

Women's Health Focus: Gynecological Cancers and Treatment Strategies

Bonnie Leo*

Department of Gynecology, Icahn School of Medicine, Mount Sinai, Australia

Corresponding author: Bonnie Leo, Department of Gynecology, Icahn School of Medicine, Mount Sinai, Australia, E-mail: leo@gmail.com

Received date: May 21, 2024, Manuscript No. IPMCR-24-19285; **Editor assigned date:** May 23, 2024, PreQC No. IPMCR-24-19285 (PQ); **Reviewed date:** June 06, 2024, QC No. IPMCR-24-19285; **Revised date:** June 13, 2024, Manuscript No. IPMCR-24-19285 (R); **Published date:** June 20, 2024, DOI: 10.36648/2471-299X.10.3.49

Citation: Leo B (2024) Women's Health Focus: Gynecological Cancers and Treatment Strategies. Med Clin Rev Vol.10 No.3: 49.

Description

Gynecological cancers refer to cancers that originate in the female reproductive system, encompassing various types that affect different organs such as the ovaries, uterus (including the cervix), fallopian tubes, vagina, and vulva. These cancers can have significant impacts on a woman's health and well-being, often requiring timely diagnosis and comprehensive treatment strategies. Ovarian cancer begins in the ovaries, which are responsible for producing eggs and hormones. It is often called the "silent killer" because symptoms may not appear until the cancer has spread beyond the ovaries. Symptoms can include abdominal bloating, pelvic pain, difficulty eating, and frequent urination. Ovarian cancer is typically diagnosed through imaging tests like ultrasound and CT scans, as well as blood tests to detect tumor markers. Uterine cancer, also known as endometrial cancer, starts in the lining of the uterus (endometrium). It is the most common gynecological cancer in developed countries. The most common symptom is abnormal vaginal bleeding, especially after menopause or between periods. Diagnostic tests include endometrial biopsy and imaging studies such as ultrasound or MRI [1-3].

Cervical cancer

Cervical cancer develops in the cervix, which is the lower part of the uterus that connects to the vagina. It is often caused by persistent infection with high-risk types of Human Papilloma Virus (HPV). Symptoms may include abnormal vaginal bleeding, pelvic pain, and pain during intercourse. Screening tests such as Pap smear and HPV testing are vital for early detection. If abnormal cells are found, further evaluation with colposcopy and biopsy may be necessary. Vulvar cancer affects the external genital area, specifically the outer lips (labia majora and labia minora), clitoris and vaginal opening. It may present as a lump or sore on the vulva, itching, pain, or bleeding not related to menstruation. Diagnosis involves biopsy of suspicious areas and imaging tests to determine the extent of the disease. Vaginal cancer originates in the vaginal lining. It is rare compared to other gynecological cancers. Symptoms include abnormal vaginal bleeding, pain during intercourse, and a lump or mass in the vagina. Diagnosis involves biopsy and imaging studies to assess the size and location of the tumor. Risk Factors and Prevention Several factors increase the risk of developing gynecological cancers Persistent infection with high-risk HPV

types increases the risk of cervical, vaginal, and vulvar cancers. The risk of gynecological cancers generally increases with age. A family history of gynecological cancers, especially ovarian and uterine cancers, can elevate individual risk. Factors such as early onset of menstruation, late menopause, infertility and not having children may increase the risk of certain gynecological cancers. Smoking is associated with an increased risk of cervical cancer [4-6].

Treatment for gynecological cancers

Treatment for gynecological cancers depends on the type and stage of cancer, as well as the patient's overall health and preferences. Options may include Surgical procedures to remove the cancerous tissue, such as hysterectomy (removal of the uterus), oophorectomy (removal of the ovaries), or lymph node dissection. Radiation may be used to kill cancer cells or shrink tumors, often used in conjunction with surgery. Drugs that target specific molecules involved in cancer growth, often used in conjunction with other treatments. Prognosis and Outlook the prognosis for gynecological cancers varies widely depending on the type and stage at diagnosis. Gynecological cancers encompass a range of malignancies affecting the female reproductive system, each with its own risk factors, symptoms, diagnostic approaches, and treatment strategies. Awareness of symptoms, regular screenings, vaccination against HPV, and lifestyle modifications can help reduce the risk of developing these cancers. Early detection and timely intervention are crucial in improving outcomes and preserving women's health. Continued research and advancements in medical science offer hope for better prevention, diagnosis, and treatment of gynecological cancers in the future [7-10].

Reference

1. Medina JE, Dracopoli NC, Bach PB, Lau A, Scharpf RB, et al. (2023) Cell-free DNA approaches for cancer early detection and interception. *J Immunother Cancer* 11.
2. Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connell JM, et al. (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. *J Clin Endocrinol Metab* 86: 2453–2455.
3. Reshko LB, Baliga S, Crandley EF, Lomas IH, Richardson MK, et al. (2020) Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers. *Gynecol Oncol* 159: 611-617.

4. Zou YG, Xu Y, Chen X, Zheng L (2023) Advances in the application of immune checkpoint inhibitors in gynecological tumors. *Int Immunopharmacol* 117: 109774.
5. Bogani G, Chiappa V, Bini M, Ronzulli D, Indini A, et al. (2022) BYL719 (alpelisib) for the treatment of *PIK3CA*-mutated, recurrent/advanced cervical cancer. *Tumori* 109: 244-248.
6. Janku F, Wheeler JJ, Westin SN, Moulder SL, Naing A, et al. (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring *PIK3CA* mutations. *J Clin Oncol* 30: 777-7782.
7. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, et al. (2018) Ovarian cancer statistics, 2018. *CA Cancer J Clin* 68: 284-296.
8. Barrington DA, Meade CE, Cosgrove CM, Cohn DE, Felix AS (2022) Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer. *Gynecol Oncol* 166: 543-551.
9. Amin SA, Collin LJ, Setoguchi S, Satagopan JM, de Meritens AB, et al. (2023) Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?. *Cancer Epidemiol Biomarkers Prev* 32: 175-182.
10. Barrington DA, Sinnott JA, Nixon D, Padamsee TJ, Cohn DE, et al. More than treatment refusal: A National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer. *Am J Obstet Gynecol* 227: 244.(e1)-244.(e17).